American Eagle Energy (NYSE: AMZG) 17.3% LOWER; The Company entered into a Forbearance Agreement with four holders, who collectively own or manage in excess of 50% of the August Notes;
Regulus Therapeutics (NASDAQ: RGLS) 9.7% HIGHER; announced the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection